Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 10: Tic, tic, tic: motor and vocal tics in a boy
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Which of the following represents an evidence-based intervention for a child with Tourette syndrome?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 155 - 172Publisher: Cambridge University PressPrint publication year: 2023
References
Bloch, M. H., Leckman, J. F. Clinical course of Tourette syndrome. J Psychosom Res 2009; 67(6): 497–501. https://doi.org/10.1016/j.jpsychores.2009.09.002Google Scholar
Brander, G., Rydell, M., Kuja-Halkola, R., et al. Perinatal risk factors in Tourette’s and chronic tic disorders: a total population sibling comparison study. Mol Psychiatry 2018; 23(5): 1189–97. https://doi.org/10.1038/mp.2017.31Google Scholar
Browne, H. A., Hansen, S. N., Buxbaum, J. D., et al. Familial clustering of tic disorders and obsessive-compulsive disorder. JAMA Psychiatry 2015; 72(4): 359–66. https://doi.org/10.1001/jamapsychiatry.2014.2656Google Scholar
Browne, H. A., Modabbernia, A., Buxbaum, J. D., et al. Prenatal maternal smoking and increased risk for Tourette syndrome and chronic tic disorders. J Am Acad Child Adolesc Psychiatry 2016; 55(9): 784–91. https://doi.org/10.1016/j.jaac.2016.06.010Google Scholar
Cavanna, A. E., David, K., Orth, M., Robertson, M. M. Predictors during childhood of future health-related quality of life in adults with Gilles de la Tourette syndrome. Eur J Paediatr Neurol 2012; 16(6): 605–12. https://doi.org/10.1016/j.ejpn.2012.02.004Google Scholar
Dalsgaard, S., Waltoft, B. L., Leckman, J. F., Mortensen, P. B. Maternal history of autoimmune disease and later development of Tourette syndrome in offspring. J Am Acad Child Adolesc Psychiatry 2015; 54(6): 495–501.e1. https://doi.org/10.1016/j.jaac.2015.03.008Google Scholar
Frankel, J., Abdullayeva, N., Mavrides, N., Coffey, B. Tic disorders. In Dulcan, M. (ed.), Dulcan’s Textbook of Child and Adolescent Psychiatry, 3rd edn. Washington DC: American Psychiatric Publishing, 2021.Google Scholar
Gancher, S., Conant-Norville, D., Angell, R. Treatment of Tourette syndrome with transdermal clonidine: a pilot study. J Neuropsychiatry Clin Neurosci 1990; 2(1): 66–69. https://doi.org/10.1176/jnp.2.1.66Google Scholar
Ghosh, D., Rajan, P. V., Das, D., et al. Sleep disorders in children with Tourette syndrome. Pediatr Neurol 2014; 51(1): 31–35. https://doi.org/10.1016/j.pediatrneurol.2014.03.017Google Scholar
Goto, R., Fujio, M., Matsuda, N., et al. The effects of comorbid Tourette symptoms on distress caused by compulsive-like behavior in very young children: a cross-sectional study. Child Adolesc Psychiatry Ment Health 2019; 13: 28. https://doi.org/10.1186/s13034-019-0290-3Google Scholar
Groth, C., Skov, L., Lange, T., Debes, N. M. Predictors of the clinical course of Tourette syndrome: a longitudinal study. J Child Neurol 2019; 34(14): 913–21. https://doi.org/10.1177/0883073819867245Google Scholar
Leckman, J. F., Hardin, M. T., Riddle, M. A., et al. Clonidine treatment of Gilles de la Tourette syndrome. Arch GenPsychiatry 1991; 48(4): 324–28. https://doi.org/10.1001/archpsyc.1991.01810280040006Google Scholar
Leckman, J. F., King, R. A., Bloch, M. H. Clinical features of Tourette syndrome and tic disorders. J Obsessive Compuls Relat Disord 2014; 3(4): 372–79. https://doi.org/10.1016/j.jocrd.2014.03.004Google Scholar
Leckman, J. F., Zhang, H., Vitale, A., et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998; 102(1 Pt 1): 14–19. https://doi.org/10.1542/peds.102.1.14Google Scholar
Mataix-Cols, D., Isomura, K., Pérez-Vigil, A., et al. Familial risks of Tourette syndrome and chronic tic disorders: a population-based cohort study. JAMA Psychiatry 2015; 72(8): 787–93. https://doi.org/10.1001/jamapsychiatry.2015.0627Google Scholar
Mathews, C. A., Scharf, J. M., Miller, L. L., et al. Association between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort. Br J Psychiatry 2014; 204(1): 40–45. https://doi.org/10.1192/bjp.bp.112.125468Google Scholar
Murphy, T. K., Fernandez, T. V., Coffey, B. J. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol 2017; 27(9): 762–70. https://doi.org/10.1089/cap.2017.0024Google Scholar
Nissen, J. B., Partner, E. T., Thomsen, P. H. Predictors of therapeutic treatment outcome in adolescent chronic tic disorders. BJPsych Open 2019; 5(5): e74. https://doi.org/10.1192/bjo.2019.56Google Scholar
Rizzo, R., Gulisano, M., Martino, D., Robertson, M. M. Gilles de la Tourette syndrome, depression, depressive illness, and correlates in a child and adolescent population. J Child Adolesc Psychopharmacol 2017; 27(3): 243–49. https://doi.org/10.1089/cap.2016.0120Google Scholar
Scahill, L., Chappell, P. B., Kim, Y. S., et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158(7): 1067–74. https://doi.org/10.1176/appi.ajp.158.7.1067Google Scholar
Shapiro, A. K., Shapiro, E., Eisenkraft, G. J. Treatment of Gilles de la Tourette syndrome with clonidine and neuroleptics. Arch Gen Psychiatry 1983; 40(11): 1235–40. https://doi.org/10.1001/archpsyc.1983.01790100081011Google Scholar
Swedo, S. E., Seidlitz, J., Kovacevic, M., et al. Clinical presentation of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections in research and community settings. J Child Adolesc Psychopharmacol 2015; 25(1): 26–30. https://doi.org/10.1089/cap.2014.0073Google Scholar